{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T11:58:19.406382",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 163,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "survival",
        "long-term survival",
        "5-year survival",
        "improved survival",
        "life years gained (LYG)",
        "deaths",
        "treatment-related mortality",
        "perioperative mortality",
        "mortality not related to hepatocellular carcinoma",
        "overall survivability"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (mRECIST)",
        "objective response rate (modified RECIST criteria)",
        "objective response rate (RECIST criteria)",
        "objective response",
        "tumor response rate",
        "tumour response rate",
        "response rates (mRECIST)",
        "response rates (RECIST)",
        "response rates (RECIST 1.1)",
        "response rates (RECIS systems)",
        "response rates (multiphase computed tomography with contrast)",
        "response rates (magnetic resonance imaging with contrast)",
        "complete response (CR)",
        "complete remission (mRECIST)",
        "partial response (PR)",
        "partial remission (mRECIST)",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "clinical benefit rate (CBR)",
        "treatment response (spiral CT or MRI, EASL modified WHO criteria)",
        "assessment of remission (mRECIST)",
        "assessment of remission (EASL classification)",
        "tumour viability (mRECIST)",
        "tumour viability (LR-TR criteria)",
        "success rate (downstaging/bridging)",
        "local control",
        "local tumour control",
        "recurrence-free survival",
        "recurrence risk after liver transplantation",
        "recurrence after hepatic resection",
        "risk of recurrence",
        "risk of tumour relapse",
        "risk of developing severe liver disease",
        "risk of developing HCC",
        "risk of co-occurrence of EKG and coronary artery disease",
        "risk of recurrence",
        "recurrence",
        "recurrence detection",
        "early detection of recurrence",
        "early detection of de novo tumor",
        "local recurrence",
        "needle tract seeding",
        "tumour seeding",
        "tumour invasion of large portal or hepatic veins",
        "extrahepatic metastasis",
        "metastases",
        "pulmonary metastasis"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "progression-free survival (RECIST 1.1)",
        "disease progression",
        "time to progression (TTP)",
        "time to tumour progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to response",
        "duration of response (DoR)",
        "duration of response (time from partial or complete response to disease progression or exit)",
        "time to deterioration",
        "time to deterioration (EORTC QLQ-C30, defined as score increase by at least 10 points over baseline)",
        "time to deterioration (EORTC QLQ-HCC18, defined as score increase by at least 10 points over baseline)",
        "time to deterioration of quality of life",
        "role functioning deterioration",
        "worsening of general condition",
        "worsening of general condition with tumour-related symptoms",
        "tumour progression",
        "improved prognosis",
        "prognosis (BCLC staging system)",
        "therapeutic efficacy"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse reactions (general)",
        "adverse reactions of grade 3 or higher",
        "adverse events (graded according to the National Cancer Institute)",
        "adverse events (grade 3 or 4)",
        "adverse events (treatment-emergent)",
        "adverse events (serious)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "grade 3-4 adverse events",
        "grade 5 adverse events",
        "treatment-related deaths",
        "treatment discontinuation due to adverse events",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "dropout rate for toxicity",
        "toxicity",
        "proteinuria toxicity",
        "haematological toxicity",
        "dermatological toxicities",
        "side-effects (general)",
        "complications",
        "major complications",
        "post-treatment complications",
        "treatment-related complications",
        "serious complications",
        "complication incidence",
        "intraoperative complications",
        "intraoperative bleeding",
        "postoperative complications",
        "postoperative decompensation",
        "morbidity",
        "bleeding",
        "haemorrhage",
        "haemorrhagic events",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "gastrointestinal perforation",
        "gastrointestinal perforations",
        "gastrointestinal disorders",
        "gastrointestinal fistulas",
        "non-gastrointestinal fistulas",
        "intestinal failure",
        "ascites",
        "abdominal swelling",
        "abdominal pain",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "joint pain",
        "back pain",
        "limb pain",
        "muscle spasms",
        "myalgia",
        "arthralgia",
        "fatigue",
        "asthenia",
        "fever",
        "infusion reaction",
        "infections",
        "influenza like illness",
        "sepsis",
        "liver failure",
        "hepatic failure",
        "hepatic impairment",
        "hepatic insufficiency",
        "liver disorders",
        "liver and biliary damages",
        "liver/biliary injuries",
        "deterioration of liver function",
        "impaired hepatic function",
        "synthetic liver function parameters",
        "liver function",
        "increased aspartate aminotransferase (AST)",
        "increased alanine aminotransferase (ALT)",
        "increased serum bilirubin",
        "increased bilirubin",
        "transient increase in transaminases",
        "pruritus",
        "rash",
        "skin rash or desquamation",
        "palmar rash",
        "dermatitis exfoliative",
        "skin desquamation",
        "dry skin",
        "erythema",
        "alopecia",
        "acne",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand feeding reactions (grade 3/4)",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "diarrhoea",
        "diarrhea",
        "nausea",
        "vomiting",
        "constipation",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro oesophageal reflux disease",
        "dysgeusia",
        "anorexia",
        "decreased appetite",
        "loss of appetite",
        "hyporexia",
        "weight loss",
        "decreased weight",
        "nutritional status",
        "nutrition disorder",
        "proteinuria",
        "renal failure",
        "renal impairment",
        "increased amylase",
        "increased lipase",
        "hypophosphataemia",
        "hypokalaemia",
        "hypokalemia",
        "hypocalcaemia",
        "hypocalcemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "QTc prolongation",
        "cardiotoxic side effects",
        "cardiotoxicity",
        "cardiac ischaemia",
        "myocardial ischaemia",
        "myocardial infarction",
        "congestive heart failure",
        "heart failure",
        "arterial hypertension",
        "hypertension",
        "hypertension (grade 3/4)",
        "arterial thromboembolic events",
        "venous thromboembolic events",
        "cerebral vascular accident",
        "cardiovascular arrest",
        "sudden death",
        "haemorrhage",
        "wound healing complications",
        "lymphoedema (grade 3/4)",
        "lymphopenia",
        "thrombocytopenia",
        "anaemia",
        "neutropenia",
        "leukopenia",
        "epilepsy",
        "headache",
        "cough",
        "dyspnoea",
        "pleural effusion",
        "respiratory failure",
        "rhinorrhoea",
        "flushing",
        "dysphonia",
        "tinnitus",
        "folliculitis",
        "erythema",
        "back pain",
        "limb pain",
        "muscle spasms",
        "myalgia",
        "arthralgia",
        "asthenia",
        "fatigue",
        "pain",
        "joint pain",
        "visual analogue scale",
        "depression",
        "peripheral sensory neuropathy",
        "secondary cancer",
        "increased carcinogenicity",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "acute generalised exanthematous pustulosis",
        "aneurysm",
        "artery dissection",
        "reversible posterior encephalopathy syndrome",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "intestinal failure",
        "proteinuria toxicity",
        "haematological toxicity",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "treatment-related deaths",
        "treatment discontinuation due to adverse events",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "dropout rate for toxicity"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "major complications",
        "treatment-related deaths",
        "treatment discontinuation due to adverse events",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "dropout rate for toxicity"
      ],
      "discontinuations": [
        "treatment discontinuation due to adverse events",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "treatment discontinuation"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (EQ-5D VAS)",
        "EQ VAS (Euro QoL visual analogue scale)",
        "EQ-5D health utility index (HUI)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep (Functional Assessment of Cancer Therapy - Hepatobiliary)",
        "SF-36",
        "visual analogue scale",
        "BPI-SF (Brief Pain Inventory – Short Form)",
        "FHSI-8 questionnaire",
        "PGI-C (Patient Global Impression of Change)",
        "Child-Pugh scale",
        "Child-Pugh score",
        "albumin-bilirubin (ALBI) score",
        "model for end-stage liver disease (MELD)",
        "MELD score",
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "performance status (ECOG/PS)"
      ],
      "functional_status": [
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "role functioning deterioration",
        "performance status (ECOG/PS)",
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "Child-Pugh scale",
        "Child-Pugh score",
        "albumin-bilirubin (ALBI) score",
        "model for end-stage liver disease (MELD)",
        "MELD score"
      ],
      "symptom_measures": [
        "symptom scales (EORTC QLQ-C30)",
        "symptom scales (EORTC QLQ-HCC18)",
        "symptoms (EORTC QLQ-C30)",
        "symptoms (EORTC QLQ-HCC18)",
        "cognitive functioning (EORTC QLQ-C30)",
        "global health status (EORTC QLQ-C30)",
        "health status (EQ-5D visual analogue scale)",
        "health-related quality of life (HRQoL)",
        "health-related quality of life",
        "health related quality of life",
        "quality of life",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "time to deterioration (score increase by at least 10 points over baseline; EORTC QLQ-C30 and EORTC QLQ-HCC18)",
        "time to deterioration (EORTC QLQ-C30, defined as score increase by at least 10 points over baseline)",
        "time to deterioration (EORTC QLQ-HCC18, defined as score increase by at least 10 points over baseline)",
        "time to deterioration of quality of life",
        "distress",
        "physical complaints",
        "psychological complaints",
        "psychosocial complaints",
        "general complaints",
        "concentration difficulties",
        "emotional impact",
        "nutritional status"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost-effectiveness (cost per QALY)",
        "incremental cost-effectiveness ratio (ICER)",
        "costs of treatment"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)"
      ],
      "resource_utilization": [
        "resource use estimates",
        "need for use of medical resources (hospital medical day)",
        "intrahospital administration",
        "outpatient regimen",
        "ambulatory regimen",
        "length of hospital stay",
        "days of missed work",
        "hospital medical day"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "number needed to treat (NNT)",
        "number needed to harm (NNH)",
        "hazard ratio (HR)",
        "mean difference (MD)",
        "relative risk (RR)",
        "risk difference (RD)",
        "treatment duration",
        "treatment response (spiral CT or MRI, EASL modified WHO criteria)",
        "success rate (downstaging/bridging)",
        "early detection of recurrence",
        "early detection of de novo tumor",
        "recurrence detection",
        "prognosis (BCLC staging system)",
        "therapeutic efficacy",
        "histological analysis",
        "molecular characterization",
        "identification of therapeutic targets",
        "staging (TNM classification)",
        "typing (WHO classification)",
        "grading (AFIP grading)",
        "grading (WHO 3-member grading)"
      ],
      "biomarkers": [
        "blood and tumour biomarker analysis",
        "alpha-fetoprotein",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "vital signs",
        "pharmacokinetic parameters",
        "plasma pharmacokinetics parameters",
        "electrocardiography"
      ]
    }
  }
}